SGLT2 inhibitors confer greater risk reductions for major adverse cardiovascular events in older adults with type 2 diabetes ...

Subin Baral, EY global life sciences deals leader, told GEN M&A deals are expected to increase in 2025, driven by biopharmas that are eager to recoup revenues they expect to lose as their aging ...

Glucagon-like peptide 1 receptor agonist use is not associated with an increased risk for thyroid cancer over the short term.

One of the most exciting developments in diabetes treatment is the use of new medications that help control blood sugar in ...

While older anti-obesity drugs may lead to less weight loss than semaglutide and tirzepatide, they remain useful tools in ...

New research suggests that Ozempic and similar weight loss medications have the potential to be as big a game changer in ...

The AP-NORC survey shows about half of U.S. adults believe it is a good thing for adults to use Ozempic, Wegovy and similar ...

Wall Street is bullish on Viking, but the company still has a lot to prove. Viking has a number of different clinical studies ...

Patients with T2D are at higher risk for adverse pregnancy outcomes like preeclampsia, preterm birth, and neonatal ...

New research uncovers hidden risks and surprising benefits of weight loss drugs like Ozempic, reshaping how we see these ...

A study confirmed that side effects like pancreatitis and kidney damage are possible while taking GLP-1s like Ozempic. Here's ...